Danaher Co. (NYSE:DHR) Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its stake in shares of Danaher Co. (NYSE:DHR) by 0.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 245,539 shares of the conglomerate’s stock after purchasing an additional 456 shares during the period. Nisa Investment Advisors LLC’s holdings in Danaher were worth $56,430,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Decker Retirement Planning Inc. acquired a new position in shares of Danaher in the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher in the 3rd quarter valued at about $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher during the 3rd quarter worth about $50,000. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter worth about $55,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on DHR. Stifel Nicolaus upped their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Barclays decreased their price objective on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Scotiabank assumed coverage on Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price for the company. Raymond James reduced their target price on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Stock Up 2.4 %

Shares of NYSE:DHR opened at $244.18 on Wednesday. The company has a market capitalization of $176.36 billion, a price-to-earnings ratio of 46.60, a price-to-earnings-growth ratio of 4.30 and a beta of 0.83. The company has a 50 day moving average of $234.75 and a two-hundred day moving average of $253.50. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52-week low of $225.42 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. As a group, analysts forecast that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.